[시장보고서]세계의 비호지킨 림프종(NHL) 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

세계의 비호지킨 림프종(NHL) 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Non-Hodgkin´s Lymphoma Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

상품코드 : 1552699

리서치사 : Transparency Market Research

발행일 : 2024년 07월

페이지 정보 : 영문 135 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,381,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 12,720,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 17,059,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

비호지킨 림프종(NHL) 치료 시장 - 조사 범위

TMR 조사 보고서 '비호지킨 림프종(NHL) 치료 세계 시장'에 대해서도 조사했습니다. 본 보고서는 2024년을 기준년, 2034년을 예측년으로 하여 2018-2034년 세계의 비호지킨 림프종(NHL) 치료 시장의 수익과 예측을 제공합니다. 또한 2024-2034년 세계 비호지킨 림프종(NHL) 치료 시장의 복합 연간 성장률(CAGR%)도 제공합니다.

이 보고서는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서 분석가는 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체와의 인터뷰를 실시했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참조하여 비호지킨 림프종(NHL) 치료 시장을 추찰했습니다.

시장 현황
2023년 시장 규모	80억 달러
2034년 시장 규모	186억 달러
CAGR	8%

이 보고서는 세계의 비호지킨 림프종(NHL) 치료 시장 경쟁 구도에 대해 파악하고 있습니다. 세계의 비호지킨 림프종(NHL) 치료 시장에서 사업을 전개하는 주요 기업이 확인되고 각 기업은 다양한 속성으로 프로파일링되고 있습니다. 기업 개요, 재무상황, 최근 동향, SWOT 등이 본 보고서에서 소개되고 있는 세계의 비호지킨 림프종(NHL) 치료 시장에서의 기업의 속성입니다.

시장기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
시장 점유율 분석 : 기업별(2023)
기업 프로파일
- Mylan NV
- Teva Pharmaceutical Industries Ltd.
- Sanofi SA
- Pfizer Inc.
- GSK plc
- Novartis AG
- Bayer AG
- Eli Lilly and Company
- Merck & Co., Inc.
- AbbVie Inc.
- AstraZeneca plc
- Johnson & Johnson Pvt. Ltd.

JHS

영문 목차

영문목차

Non-Hodgkin's Lymphoma Therapeutics Market - Scope of Report

TMR's report on the global non-Hodgkin's lymphoma therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global non-Hodgkin's lymphoma therapeutics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-Hodgkin's lymphoma therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the non-Hodgkin's lymphoma therapeutics market.

Market Snapshot
Market Value in 2023	US$ 8 Bn
Market Value in 2034	US$ 18.6 Bn
CAGR	8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global non-Hodgkin's lymphoma therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global non-Hodgkin's lymphoma therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global non-Hodgkin's lymphoma therapeutics market.

The report delves into the competitive landscape of the global non-Hodgkin's lymphoma therapeutics market. Key players operating in the global non-Hodgkin's lymphoma therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global non-Hodgkin's lymphoma therapeutics market profiled in this report.

Key Questions Answered in Global non-Hodgkin's lymphoma therapeutics Market Report:

What is the sales/revenue generated by non-Hodgkin's lymphoma therapeutics across all regions during the forecast period?
What are the opportunities in the global non-Hodgkin's lymphoma therapeutics market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Non-Hodgkin's Lymphoma Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global non-Hodgkin's lymphoma therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global non-Hodgkin's lymphoma therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global non-Hodgkin's lymphoma therapeutics market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Non-Hodgkin's Lymphoma Therapeutics Market

4. Market Overview

4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, 2020-2034

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Treatment Therapy

6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Therapy, 2020-2034
- 6.3.1. Chemotherapy
- 6.3.2. Targeted Therapy
- 6.3.3. Immunotherapy
- 6.3.4. Others (Radiation Therapy, etc.)
6.4. Market Attractiveness, by Treatment Therapy

7. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Indication Type

7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication Type, 2020-2034
- 7.3.1. B-Cell Lymphomas
- 7.3.2. T-Cell Lymphomas
7.4. Market Attractiveness, by Indication Type

8. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Route of Administration

8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
- 8.3.1. Oral
- 8.3.2. Parenteral
8.4. Market Attractiveness, by Route of Administration

9. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by End-user

9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail Pharmacies
- 9.3.3. Online Pharmacies
9.4. Market Attractiveness, by End-user

10. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Region

10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region

11. North America Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Therapy, 2020-2034
- 11.2.1. Chemotherapy
- 11.2.2. Targeted Therapy
- 11.2.3. Immunotherapy
- 11.2.4. Others (Radiation Therapy, etc.)
11.3. Market Attractiveness, by Treatment Therapy
11.4. Market Value Forecast, by Indication Type, 2020-2034
- 11.4.1. B-Cell Lymphomas
- 11.4.2. T-Cell Lymphomas
11.5. Market Attractiveness, by Indication Type
11.6. Market Value Forecast, by Route of Administration, 2020-2034
- 11.6.1. Oral
- 11.6.2. Parenteral
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by End-user, 2020-2034
- 11.8.1. Hospital Pharmacies
- 11.8.2. Retail Pharmacies
- 11.8.3. Online Pharmacies
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 11.10.1. U.S.
- 11.10.2. Canada
11.11. Market Attractiveness Analysis
- 11.11.1. By Treatment Therapy
- 11.11.2. By Indication Type
- 11.11.3. By Route of Administration
- 11.11.4. By End-user
- 11.11.5. By Country

12. Europe Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Therapy, 2020-2034
- 12.2.1. Chemotherapy
- 12.2.2. Targeted Therapy
- 12.2.3. Immunotherapy
- 12.2.4. Others (Radiation Therapy, etc.)
12.3. Market Attractiveness, by Treatment Therapy
12.4. Market Value Forecast, by Indication Type, 2020-2034
- 12.4.1. B-Cell Lymphomas
- 12.4.2. T-Cell Lymphomas
12.5. Market Attractiveness, by Indication Type
12.6. Market Value Forecast, by Route of Administration, 2020-2034
- 12.6.1. Oral
- 12.6.2. Parenteral
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by End-user, 2020-2034
- 12.8.1. Hospital Pharmacies
- 12.8.2. Retail Pharmacies
- 12.8.3. Online Pharmacies
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 12.10.1. Germany
- 12.10.2. U.K.
- 12.10.3. France
- 12.10.4. Italy
- 12.10.5. Spain
- 12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
- 12.11.1. By Treatment Therapy
- 12.11.2. By Indication Type
- 12.11.3. By Route of Administration
- 12.11.4. By End-user
- 12.11.5. By Country/Sub-region

13. Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Therapy, 2020-2034
- 13.2.1. Chemotherapy
- 13.2.2. Targeted Therapy
- 13.2.3. Immunotherapy
- 13.2.4. Others (Radiation Therapy, etc.)
13.3. Market Attractiveness, by Treatment Therapy
13.4. Market Value Forecast, by Indication Type, 2020-2034
- 13.4.1. B-Cell Lymphomas
- 13.4.2. T-Cell Lymphomas
13.5. Market Attractiveness, by Indication Type
13.6. Market Value Forecast, by Route of Administration, 2020-2034
- 13.6.1. Oral
- 13.6.2. Parenteral
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by End-user, 2020-2034
- 13.8.1. Hospital Pharmacies
- 13.8.2. Retail Pharmacies
- 13.8.3. Online Pharmacies
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 13.10.1. China
- 13.10.2. Japan
- 13.10.3. India
- 13.10.4. Australia & New Zealand
- 13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
- 13.11.1. By Treatment Therapy
- 13.11.2. By Indication Type
- 13.11.3. By Route of Administration
- 13.11.4. By End-user
- 13.11.5. By Country/Sub-region

14. Latin America Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Therapy, 2020-2034
- 14.2.1. Chemotherapy
- 14.2.2. Targeted Therapy
- 14.2.3. Immunotherapy
- 14.2.4. Others (Radiation Therapy, etc.)
14.3. Market Attractiveness, by Treatment Therapy
14.4. Market Value Forecast, by Indication Type, 2020-2034
- 14.4.1. B-Cell Lymphomas
- 14.4.2. T-Cell Lymphomas
14.5. Market Attractiveness, by Indication Type
14.6. Market Value Forecast, by Route of Administration, 2020-2034
- 14.6.1. Oral
- 14.6.2. Parenteral
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by End-user, 2020-2034
- 14.8.1. Hospital Pharmacies
- 14.8.2. Retail Pharmacies
- 14.8.3. Online Pharmacies
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 14.10.1. Brazil
- 14.10.2. Mexico
- 14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
- 14.11.1. By Treatment Therapy
- 14.11.2. By Indication Type
- 14.11.3. By Route of Administration
- 14.11.4. By End-user
- 14.11.5. By Country/Sub-region

15. Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment Therapy, 2020-2034
- 15.2.1. Chemotherapy
- 15.2.2. Targeted Therapy
- 15.2.3. Immunotherapy
- 15.2.4. Others (Radiation Therapy, etc.)
15.3. Market Attractiveness, by Treatment Therapy
15.4. Market Value Forecast, by Indication Type, 2020-2034
- 15.4.1. B-Cell Lymphomas
- 15.4.2. T-Cell Lymphomas
15.5. Market Attractiveness, by Indication Type
15.6. Market Value Forecast, by Route of Administration, 2020-2034
- 15.6.1. Oral
- 15.6.2. Parenteral
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by End-user, 2020-2034
- 15.8.1. Hospital Pharmacies
- 15.8.2. Retail Pharmacies
- 15.8.3. Online Pharmacies
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 15.10.1. GCC Countries
- 15.10.2. South Africa
- 15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
- 15.11.1. By Treatment Therapy
- 15.11.2. By Indication Type
- 15.11.3. By Route of Administration
- 15.11.4. By End-user
- 15.11.5. By Country/Sub-region

16. Competition Landscape

16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
- 16.3.1. Mylan N.V.
  - 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.1.2. Product Portfolio
  - 16.3.1.3. Financial Overview
  - 16.3.1.4. SWOT Analysis
  - 16.3.1.5. Strategic Overview
- 16.3.2. Teva Pharmaceutical Industries Ltd.
  - 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.2.2. Product Portfolio
  - 16.3.2.3. Financial Overview
  - 16.3.2.4. SWOT Analysis
  - 16.3.2.5. Strategic Overview
- 16.3.3. Sanofi S.A.
  - 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.3.2. Product Portfolio
  - 16.3.3.3. Financial Overview
  - 16.3.3.4. SWOT Analysis
  - 16.3.3.5. Strategic Overview
- 16.3.4. Pfizer Inc.
  - 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.4.2. Product Portfolio
  - 16.3.4.3. Financial Overview
  - 16.3.4.4. SWOT Analysis
  - 16.3.4.5. Strategic Overview
- 16.3.5. GSK plc
  - 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.5.2. Product Portfolio
  - 16.3.5.3. Financial Overview
  - 16.3.5.4. SWOT Analysis
  - 16.3.5.5. Strategic Overview
- 16.3.6. Novartis AG
  - 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.6.2. Product Portfolio
  - 16.3.6.3. Financial Overview
  - 16.3.6.4. SWOT Analysis
  - 16.3.6.5. Strategic Overview
- 16.3.7. Bayer AG
  - 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.7.2. Product Portfolio
  - 16.3.7.3. Financial Overview
  - 16.3.7.4. SWOT Analysis
  - 16.3.7.5. Strategic Overview
- 16.3.8. Eli Lilly and Company
  - 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.8.2. Product Portfolio
  - 16.3.8.3. Financial Overview
  - 16.3.8.4. SWOT Analysis
  - 16.3.8.5. Strategic Overview
- 16.3.9. Merck & Co., Inc.
  - 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.9.2. Product Portfolio
  - 16.3.9.3. Financial Overview
  - 16.3.9.4. SWOT Analysis
  - 16.3.9.5. Strategic Overview
- 16.3.10. AbbVie Inc.
  - 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.10.2. Product Portfolio
  - 16.3.10.3. Financial Overview
  - 16.3.10.4. SWOT Analysis
  - 16.3.10.5. Strategic Overview
- 16.3.11. AstraZeneca plc
  - 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.11.2. Product Portfolio
  - 16.3.11.3. Financial Overview
  - 16.3.11.4. SWOT Analysis
  - 16.3.11.5. Strategic Overview
- 16.3.12. Johnson & Johnson Pvt. Ltd.
  - 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.12.2. Product Portfolio
  - 16.3.12.3. Financial Overview
  - 16.3.12.4. SWOT Analysis
  - 16.3.12.5. Strategic Overview

한글목차

비호지킨 림프종(NHL) 치료 시장 - 조사 범위

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약: 세계 시장

제4장 시장 개요

제5장 주요 인사이트

제6장 세계 시장 분석과 예측 : 치료별

제7장 세계 시장 분석과 예측 : 적응증 유형별

제8장 세계 시장 분석과 예측 : 투여 경로별

제9장 세계 시장 분석과 예측 : 최종 사용자별

제10장 세계 시장 분석과 예측 : 지역별

제11장 북미 시장 분석과 예측

제12장 유럽 시장 분석과 예측

제13장 아시아태평양 시장 분석과 예측

제14장 라틴아메리카 시장 분석과 예측

제15장 중동 및 아프리카 시장 분석과 예측

제16장 경쟁 구도